Project Grant R03HL174883
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$117K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $169,156 to The Washington University in St. Louis to support a 5-year research program focused on optimizing hematopoietic stem cell transplantation (HSCT) to treat non-malignant diseases, particularly sickle cell disease (SCD). The key objectives are to: 1) Evaluate novel stem cell mobilization regimens combining VLA-4 and CXCR4 inhibition to generate...
This $758,539 Project Grant, awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to The Leland Stanford Junior University, aims to identify the mechanistic pathways leading to the generation and release of dysfunctional mitochondria during pre-hematopoietic stem cell transplantation (HSCT) conditioning. The goal is to discover new therapeutic targets to prevent graft-versus-host disease (GVHD), a leading cause of non-relapse mortality following...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $814,209 to the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) to develop CD90-targeted nanoparticles for in vivo hematopoietic stem cell gene therapy. The key objectives are to: 1) optimize nanoparticle formulations loaded with gene-editing agents and functionalize them for targeting, 2) evaluate the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,999,247 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Childrens Hospital Medical Center in Cincinnati, OH. The grant, entitled "Allogeneic Virus-Specific T-Cell Therapy After Hematopoietic Stem Cell Transplant: Determinants of Treatment Success and Failure", aims to improve understanding of the mechanisms underlying success and failure of virus-specific T-cell (VST) therapy in...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $792,498 to the Trustees of Indiana University, Indianapolis (IU Indianapolis) to conduct research on hematopoietic stem cells (HSCs) and their regulation under low oxygen tension (hypoxia). The primary goals are to: 1) understand how hypoxia activates the transcription factor TFE3 to facilitate HSC self-renewal, 2) determine...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $380,383 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Johns Hopkins University. The 3-year grant, awarded on Apr 21, 2025, aims to investigate the role of aldehyde-detoxifying enzymes in protecting hematopoietic stem cells (HSCs) from endogenous DNA damage, with the goal of developing novel therapeutic strategies to prevent bone marrow failure and malignancies in Fanconi anemia patients....
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $153,117 to support a 5-year research project focused on improving hematopoietic stem cell (HSPC) transplantation outcomes. The goal is to investigate mechanisms of HSPC-niche cell crosstalk, specifically how HSPC-derived extracellular vesicles promote remodeling of bone marrow endothelial cells and migration of HSPCs. The...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to evaluate methods for improving the homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The $128,100 award to the New York Blood Center, Inc. will support research to determine if co-infusing the CD34+ cells with their flow-through accessory cells, normally discarded after CD34+ cell...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,123,357.00 to support research on the bone marrow microenvironment and its role in regulating blood cell production. The research, to be conducted by the Children's Hospital Medical Center in Cincinnati, Ohio, aims to define the spatial organization and specialized vascular microenvironments within the bone marrow that recruit and...
This federal Project Grant award, valued at $166,644.00 and awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the functional and molecular consequences of aging and TET2 mutations on human hematopoietic stem cell responses to inflammatory cytokines like IL-1β. The research aims to provide a comprehensive understanding of how these factors alter inflammatory response pathways, leading...